Daisy Genomics

Executive Summary

Daisy Genomics, a San Diego-based private biotechnology company founded in 2020, is developing a transformative genomic analysis platform that integrates nanofluidics with enhanced Raman spectroscopy. Unlike conventional sequencing methods that require amplification or labeling, Daisy's technology enables direct, long-read sequencing of native DNA, capturing critical epigenetic modifications often missed by current approaches. This capability holds promise for advancing precision medicine by providing a more complete picture of the genome and its regulatory layers. The platform aims to address limitations in detecting structural variants, repeat expansions, and base modifications in a single, label-free assay, potentially improving diagnostics and therapeutic development in oncology, rare diseases, and beyond. The company operates in the competitive genomics space but differentiates itself through its novel chemistry and nanoscale detection. As an early-stage venture with no disclosed funding or partnerships, its immediate focus is likely on technical validation and proof-of-concept studies. Key milestones ahead include demonstrating platform performance on clinically relevant samples, attracting strategic investors, and establishing collaborations. While the technology is promising, the path to commercialization involves significant technical and regulatory hurdles. The conviction score reflects cautious optimism given the early stage and lack of public data.

Upcoming Catalysts (preview)

• 2026Series A Funding Announcement70% success
• 2026Peer-Reviewed Publication of Proof-of-Concept Data60% success
• 2027Collaboration with Academic Research Center or Pharma40% success